Vor Biopharma
Manufacturing · 11-50 Employees
View Company Info for Free
Overview
Phone Number
(617) 655-6580Website
www.vorbiopharma.comRevenue
$5.7 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Vor Biopharma
Vor Bio, also known as Vor Biopharma, is a biotechnology company focused on curing blood cancers through cell and genome engineering. They develop innovative shielded transplants that allow for potentially curative treatments post-transplant, particularly for patients with Acute Myeloid Leukemia (AML) and other blood cancers. Their proprietary platform leverages Hematopoietic Stem Cell (HSC) biology, genome engineering, and CAR-T cells to create targeted therapies that differentiate between healthy and cancerous cells. Vor Bio aims to transform the treatment landscape for blood cancer patients while addressing urgent unmet medical needs.Explore more
Popular SearchesVor BiopharmaVor Biopharma IncSIC Code 28,283NAICS Code 32,325Show moreSell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Vor Biopharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Vor Biopharma
Earning: See what the market has to say on Vor Biopharma recently announced quarterly report
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Vor Biopharma has new funding data
Check if Vor Biopharma has recently received funding, and reach out quickly before it becomes old news!
Check out if Vor Biopharma is spiking on competitors!
Product Launch: Get notified when Vor Biopharma launches new products
Click to see if Vor Biopharma had a recent Job posting/layoffs
Vor Biopharma, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Vor Biopharma
Find 2 more new buyers
Compare Similar Companies to Vor Biopharma
Compare insights from companies similar to Vor Biopharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Vor Biopharma
$5.7M
11-50
Private
$75M
-
N/A
Company Profile Activity
Activity Insights
Vor Biopharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Vor Biopharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Vor Biopharma.
Vor Biopharma financials insights
Gather financial insights about Vor Biopharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2026
Stock/Share Issuance
$75M
Vor Biopharma Tech Stack
A closer look at the technologies used by Vor Biopharma
Most Recent Scoops
Funding
Funding
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Vor Biopharma News & Media
Vor Biopharma Inc. (VOR) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Vor Biopharma Inc. (VOR) TD Cowen 46th Annual Health Care Conference March 2, 2026 9:50 AM ESTCompany ParticipantsJean-Paul Kress - Chairman &...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Vor Biopharma
Sign Up For FreeTo access detailed company insights
Vor Bio, also known as Vor Biopharma, is a biotechnology company focused on curing blood cancers through cell and genome engineering. They develop innovative shielded transplants that allow for potentially curative treatments post-transplant, particularly for patients with Acute Myeloid Leukemia (AML) and other blood cancers. Their proprietary plat... Read More
